Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BPMUFNASDAQ:CBAYOTCMKTS:INVVYNASDAQ:PRQR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$44.45$41.49$38.60▼$44.45$526.79M0.655 shsN/ACBAYCymaBay Therapeutics$32.48$32.39$7.26▼$32.50$3.73B0.324.11 million shs73 shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPRQRProQR Therapeutics$1.94-3.5%$2.14$1.11▼$3.29$157.84M0.21274,959 shs86,156 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+9.08%+15.16%-14.52%CBAYCymaBay Therapeutics0.00%0.00%0.00%+44.61%+229.08%INVVYIndivior0.00%0.00%0.00%0.00%-7.28%PRQRProQR Therapeutics-0.50%+5.79%-15.90%-3.83%-9.46%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay Therapeutics0.9323 of 5 stars2.00.00.04.70.02.50.6INVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics1.4728 of 5 stars3.54.00.00.01.90.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea PharmaceuticaN/AN/AN/AN/ACBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideINVVYIndiviorN/AN/AN/AN/APRQRProQR Therapeutics3.00Buy$3.6085.57% UpsideCurrent Analyst RatingsLatest PRQR, CBAY, INVVY, and BPMUF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.50(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PRQRProQR Therapeutics$7.05M22.39N/AN/A$0.55 per share3.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)Latest PRQR, CBAY, INVVY, and BPMUF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 million2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea PharmaceuticaN/A3.202.64CBAYCymaBay TherapeuticsN/A10.9610.96INVVYIndiviorN/AN/AN/APRQRProQR Therapeutics0.103.543.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ACBAYCymaBay Therapeutics95.03%INVVYIndivior0.05%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ACBAYCymaBay Therapeutics7.00%INVVYIndiviorN/APRQRProQR Therapeutics8.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionablePRQR, CBAY, INVVY, and BPMUF HeadlinesSourceHeadlineProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meetingstockhouse.com - April 24 at 10:59 AMProQR defends RNA editing platform at EPOlifesciencesipreview.com - April 23 at 2:29 PMProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024globenewswire.com - April 23 at 7:00 AMComparing ProQR Therapeutics (NASDAQ:PRQR) & Teva Pharmaceutical Industries (NYSE:TEVA)americanbankingnews.com - April 23 at 1:44 AMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingfinance.yahoo.com - April 22 at 4:41 PMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingglobenewswire.com - April 22 at 4:31 PMProQR retains key patent for RNA editing technologyuk.investing.com - April 21 at 10:34 PMProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfoliostockhouse.com - April 20 at 8:50 PMCitigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00americanbankingnews.com - April 20 at 4:50 AMProQR defends its Axiomer IP portfolio from new challengethepharmaletter.com - April 19 at 3:54 PMProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolioglobenewswire.com - April 19 at 7:00 AMProQR Therapeutics gets grant for oligonucleotide for reducing aberrant splice site selection in CEP290 genepharmaceutical-technology.com - April 18 at 1:28 PMCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00marketbeat.com - April 18 at 12:13 PMProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above Fifty Day Moving Average of $2.16americanbankingnews.com - April 16 at 3:56 AMProQR Therapeutics N.V. (PRQR)finance.yahoo.com - April 8 at 10:59 AMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 29 at 2:14 AMBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disordersmarkets.businessinsider.com - March 14 at 7:10 PMBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platformmarkets.businessinsider.com - March 14 at 9:09 AMProQR Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 14 at 9:09 AMProQR Announces Year End 2023 Operating and Financial Resultsglobenewswire.com - March 13 at 7:00 AMProQR Therapeutics gets grant for nucleic acid molecule for converting uridine to pseudouridinepharmaceutical-technology.com - March 5 at 10:34 AMPRQR Mar 2024 2.500 callfinance.yahoo.com - February 18 at 1:10 PMProQR Therapeutics N.V.wsj.com - February 16 at 8:41 AMProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editingfinance.yahoo.com - February 15 at 8:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBasilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.CymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.